scispace - formally typeset
E

Erika Ziegler

Researcher at Saarland University

Publications -  5
Citations -  135

Erika Ziegler is an academic researcher from Saarland University. The author has contributed to research in topics: Dehydrogenase & Estrogen. The author has an hindex of 4, co-authored 5 publications receiving 133 citations.

Papers
More filters
Journal ArticleDOI

New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.

TL;DR: Inhibition of 17β-HSD1 inhibitors from the hydroxyphenylnaphthol class by introduction of different heteroaromatic rings as well as substituted phenyl groups showed a good membrane permeation and metabolic stability and was orally available in the rat.
Patent

17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases

TL;DR: In this article, the 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the production thereof, and the use thereof for treating and preventing hormone-dependent, especially estrogen-dependent or androgen-dependent diseases.
Journal ArticleDOI

Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors

TL;DR: Using a structure- and ligand-based approach, a pharmacophore model was proposed and a new class of non-steroidal inhibitors of 17beta-HSD1 was designed, and the potency of this class of inhibitors was improved by substitution of the 1-position of the naphthalene ring by a phenyl group.
Journal ArticleDOI

Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations

TL;DR: Highly active and selective inhibitors of the human 17βHSD1 with promising properties for further preclinical development have been identified and the development of two assays for determination of E2-activation and -inactivation are described.
Patent

17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen

TL;DR: In this paper, the Verwendung von nicht-steroidalen 17Beta-Hydroxysteroid-Dehydrogenase-Typ 1-Inhibitoren zur Behandlung and Prophylaxe hormonabhangiger, insbesondere estrogenabhanginger Erkrankungen is investigated.